<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Clinical manifestations and diagnosis of gastroesophageal reflux in adults</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Clinical manifestations and diagnosis of gastroesophageal reflux in adults</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Clinical manifestations and diagnosis of gastroesophageal reflux in adults</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter J Kahrilas, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Nicholas J Talley, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Shilpa Grover, MD, MPH, AGAF</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 15, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Gastroesophageal reflux disease (GERD) is notable for its high prevalence, variety of clinical presentations, under-recognized morbidity, and substantial economic consequences. </p><p>This topic will review the clinical manifestations and diagnosis of GERD. The pathophysiology and management of GERD are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/2257.html" rel="external">"Pathophysiology of reflux esophagitis"</a> and  <a class="medical medical_review" href="/z/d/html/2258.html" rel="external">"Medical management of gastroesophageal reflux disease in adults"</a> and  <a class="medical medical_review" href="/z/d/html/2278.html" rel="external">"Surgical treatment of gastroesophageal reflux in adults"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">TERMINOLOGY</span><span class="headingEndMark"> — </span>Some degree of reflux is physiologic [<a href="#rid1">1</a>]. Physiologic reflux episodes typically occur postprandially, are short-lived, asymptomatic, and rarely occur during sleep. </p><p>Pathologic reflux is associated with symptoms or mucosal injury and often occurs nocturnally.</p><p class="bulletIndent1"><span class="glyph">●</span>Gastroesophageal reflux disease (GERD) is a condition that develops when the reflux of stomach contents causes troublesome symptoms and/or complications [<a href="#rid2">2</a>]. </p><p></p><p>GERD is classified based on the appearance of the esophageal mucosa on upper endoscopy into the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Erosive esophagitis</strong> — Erosive esophagitis is characterized by endoscopically visible breaks in the distal esophageal mucosa with or without troublesome symptoms of GERD. (See <a class="local">'Endoscopic findings'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nonerosive reflux disease</strong> — Nonerosive reflux disease or endoscopy negative reflux disease is characterized by the presence of troublesome symptoms of GERD without visible esophageal mucosal injury.</p><p></p><p class="headingAnchor" id="H3"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>In a systematic review of 15 epidemiological studies, the prevalence of gastroesophageal reflux disease (GERD) was found to be 10 to 20 percent in the Western world and less than 5 percent in Asia [<a href="#rid3">3</a>]. The incidence in the Western world was approximately five per 1000 person-years or 0.5 percent per year. In a subsequent population-based survey in the United States, 22 percent of respondents reported that they had heartburn or regurgitation within the last month while 16 percent reported regurgitation [<a href="#rid4">4</a>]. Heartburn or regurgitation was clinically significant (≥twice weekly) in 6 and 3 percent, respectively.</p><p>There are limitations in the epidemiologic estimates of the prevalence of GERD, as they are based upon the assumption that heartburn and/or regurgitation are the only indicators of the disease [<a href="#rid3">3,4</a>]. However, patients with objective evidence of GERD (eg, esophagitis or Barrett's esophagus) do not always have heartburn and heartburn is not always sufficiently severe to be indicative of GERD [<a href="#rid5">5</a>].</p><p class="headingAnchor" id="H13576047"><span class="h1">CLINICAL FEATURES</span></p><p class="headingAnchor" id="H4"><span class="h2">Clinical manifestations</span><span class="headingEndMark"> — </span>Classic symptoms of gastroesophageal reflux disease (GERD) are heartburn (pyrosis) and regurgitation. </p><p class="bulletIndent1"><span class="glyph">●</span>Heartburn is typically described as a burning sensation in the retrosternal area, most commonly experienced in the postprandial period [<a href="#rid2">2</a>]. Heartburn is considered troublesome if symptoms occur two or more days a week [<a href="#rid2">2</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Regurgitation is defined as the perception of flow of refluxed gastric content into the mouth or hypopharynx [<a href="#rid2">2</a>]. Patients typically regurgitate acidic material mixed with small amounts of undigested food.</p><p></p><p>Other symptoms of GERD include dysphagia, chest pain, water brash, globus sensation, odynophagia, extraesophageal symptoms (eg, chronic cough, hoarseness, wheezing), and, infrequently, nausea.</p><p class="bulletIndent1"><span class="glyph">●</span>Dysphagia is common in the setting of longstanding heartburn and is often attributable to reflux esophagitis but can be indicative of an esophageal stricture [<a href="#rid6">6</a>]. Odynophagia is an unusual symptom of GERD but, when present, usually indicates an esophageal ulcer. (See  <a class="medical medical_review" href="/z/d/html/2241.html" rel="external">"Approach to the evaluation of dysphagia in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>GERD-related chest pain can mimic angina pectoris, and is typically described as squeezing or burning, located substernally and radiating to the back, neck, jaw, or arms. The pain can last anywhere from minutes to hours and resolve either spontaneously or with antacids. It usually occurs after meals, awakens patients from sleep, and may be exacerbated by emotional stress [<a href="#rid1">1</a>]. Patients with reflux-induced chest pain may also have typical reflux symptoms. However, heartburn is a poor predictor of whether patients with chest pain have evidence of GERD by objective reflux testing (eg, esophageal pH monitoring) [<a href="#rid7">7</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Water brash or hypersalivation is a relatively unusual symptom in which patients can foam at the mouth, secreting as much as 10 mL of saliva per minute in response to reflux.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Globus sensation is the almost constant perception of a lump in the throat (irrespective of swallowing), which has been related to GERD in some studies. However, the role of esophageal reflux in globus is uncertain [<a href="#rid8">8</a>]. (See  <a class="medical medical_review" href="/z/d/html/2240.html" rel="external">"Globus sensation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Nausea is infrequently reported with GERD, but a diagnosis of GERD should be considered in patients with otherwise unexplained nausea [<a href="#rid9">9</a>]. (See  <a class="medical medical_review" href="/z/d/html/2537.html" rel="external">"Approach to the adult with nausea and vomiting", section on 'Gastroesophageal reflux'</a>.)</p><p></p><p class="headingAnchor" id="H13576252"><span class="h2">Radiographic findings</span><span class="headingEndMark"> — </span>Double contrast <a class="drug drug_general" data-topicid="9180" href="/z/d/drug information/9180.html" rel="external">barium</a> swallow examination is of limited diagnostic utility in patients with GERD. The demonstration of reflux of barium during the study is of dubious significance since it can be provoked in 25 to 71 percent of symptomatic patients and 20 percent of normal controls [<a href="#rid10">10</a>]. In one study, the diagnostic accuracy of barium radiography in patients with mild, moderate, and severe esophagitis on upper endoscopy is 25, 82 percent, and 99 percent, respectively [<a href="#rid11">11</a>]. </p><p>Mucosal changes associated with esophagitis and peptic strictures seen on double contrast <a class="drug drug_general" data-topicid="9180" href="/z/d/drug information/9180.html" rel="external">barium</a> radiography include the following: </p><p class="bulletIndent1"><span class="glyph">●</span>In early stages of reflux esophagitis, the mucosa of the distal third of the esophagus appears granular or nodular with numerous ill-defined, 1 to 3 mm lucencies [<a href="#rid12">12</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients with erosive esophagitis, shallow ulcers and erosions may be visualized as tiny collections of <a class="drug drug_general" data-topicid="9180" href="/z/d/drug information/9180.html" rel="external">barium</a> in the distal esophagus near the gastroesophageal junction, sometimes surrounded by a radiolucent halo of edematous mucosa.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A benign peptic stricture due to GERD has the appearance of a smooth, tapered area of concentric narrowing in the distal esophagus that is usually 1 to 4 cm in length and 0.2 to 2.0 cm in diameter  (<a class="graphic graphic_diagnosticimage graphicRef66161" href="/z/d/graphic/66161.html" rel="external">image 1</a>). However, many peptic strictures have an asymmetric appearance with puckering of one wall of the stricture due to eccentric scarring.</p><p></p><p class="headingAnchor" id="H3612456294"><span class="h2">Complications</span><span class="headingEndMark"> — </span>Complications from GERD can arise even in patients who lack typical esophageal symptoms. These complications may be esophageal (eg, Barrett’s esophagus, esophageal stricture, esophageal adenocarcinoma) or extra-esophageal (eg, chronic laryngitis, exacerbation of asthma). (See  <a class="medical medical_review" href="/z/d/html/2263.html" rel="external">"Complications of gastroesophageal reflux in adults"</a>.)</p><p class="headingAnchor" id="H1615711316"><span class="h1">DIAGNOSIS</span></p><p class="headingAnchor" id="H450982140"><span class="h2">Patients with classic symptoms</span><span class="headingEndMark"> — </span>The diagnosis of gastroesophageal reflux disease (GERD) can often be based on clinical symptoms alone in patients with classic symptoms such as heartburn and/or regurgitation [<a href="#rid2">2,13</a>]. However, patients may require additional evaluation if they have alarm features, risk factors for Barrett’s esophagus, or abnormal gastrointestinal imaging performed for evaluation of their symptoms. (See <a class="local">'Evaluation in selected patients'</a> below.)</p><p>Although 40 to 90 percent of patients with symptoms suggestive of GERD have a symptomatic response to proton pump inhibitors (PPIs), a response to antisecretory therapy is not a diagnostic criterion for GERD [<a href="#rid14">14,15</a>]. A meta-analysis of diagnostic test characteristics found that a response to PPIs did not correlate well with objective measures of GERD such as ambulatory pH monitoring [<a href="#rid15">15</a>]. Pooled sensitivity and specificity were 78 and 54 percent, respectively. Thus, a response to PPIs does not correspond to a GERD diagnosis based on reflux testing. </p><p class="headingAnchor" id="H2486882094"><span class="h2">Patients without classic symptoms</span><span class="headingEndMark"> — </span>Other symptoms (eg, chest pain, globus sensation, chronic cough, hoarseness, wheezing, and nausea) may be seen in the setting of GERD, but are not sufficient to make a clinical diagnosis of GERD in the absence of classic symptoms of heartburn and regurgitation. Other disorders need to be excluded before attributing the symptoms to GERD. As an example, unexplained chest pain should be evaluated with an electrocardiogram and exercise stress test prior to a gastrointestinal evaluation.</p><p class="headingAnchor" id="H4136578667"><span class="h1">EVALUATION IN SELECTED PATIENTS</span><span class="headingEndMark"> — </span>Additional evaluation is required in selected patients with suspected gastroesophageal reflux disease (GERD) to rule out alternative etiologies, confirm the diagnosis of GERD, and assess for complications (eg, Barrett’s esophagus). (See  <a class="medical medical_review" href="/z/d/html/2263.html" rel="external">"Complications of gastroesophageal reflux in adults"</a>.)</p><p class="headingAnchor" id="H7"><span class="h2">Upper gastrointestinal endoscopy</span></p><p class="headingAnchor" id="H2825835698"><span class="h3">Indications</span><span class="headingEndMark"> — </span>Upper endoscopy is indicated in patients with suspected GERD to evaluate alarm features or abnormal imaging if not performed within the last three months. Upper endoscopy should also be performed to screen for Barrett’s esophagus in patients with risk factors. On upper endoscopy, biopsies should target any areas of suspected metaplasia, dysplasia, or, in the absence of visual abnormalities, normal mucosa to evaluate for eosinophilic esophagitis [<a href="#rid16">16</a>]. (See <a class="local">'Alarm features'</a> below and <a class="local">'Risk factors for Barrett's esophagus'</a> below and <a class="local">'Abnormal upper gastrointestinal tract imaging'</a> below.) <span class="utd-adt-cnt utd-adt-pathwys utd-content-120419">(Related Pathway(s):  <a class="utd-content-120419" href="/pathway/120419?topicRef=2265&amp;source=see_link">Gastroesophageal reflux disease: Identification of adults who require upper endoscopy</a>.)</span></p><p>Upper endoscopy is not required to make a diagnosis of GERD. However, upper endoscopy can detect esophageal manifestations of GERD (eg, Barrett’s metaplasia, erosive esophagitis) and can rule out an upper gastrointestinal tract malignancy. Upper endoscopy can also rule out other etiologies in patients with GERD symptoms that are refractory to a trial of proton pump inhibitor (PPI) therapy. (See  <a class="medical medical_review" href="/z/d/html/2239.html" rel="external">"Approach to refractory gastroesophageal reflux disease in adults", section on 'Diagnostic strategies and initial management'</a> and  <a class="medical medical_review" href="/z/d/html/2258.html" rel="external">"Medical management of gastroesophageal reflux disease in adults", section on 'Pretreatment evaluation'</a>.) </p><p class="headingAnchor" id="H1121273268"><span class="h4">Alarm features</span><span class="headingEndMark"> — </span>Alarm features that are suggestive of a gastrointestinal malignancy include:</p><p class="bulletIndent1"><span class="glyph">●</span>New onset of dyspepsia in patient ≥60 years</p><p class="bulletIndent1"><span class="glyph">●</span>Evidence of gastrointestinal bleeding (hematemesis, melena, hematochezia, occult blood in stool)</p><p class="bulletIndent1"><span class="glyph">●</span>Iron deficiency anemia </p><p class="bulletIndent1"><span class="glyph">●</span>Anorexia</p><p class="bulletIndent1"><span class="glyph">●</span>Unexplained weight loss</p><p class="bulletIndent1"><span class="glyph">●</span>Dysphagia</p><p class="bulletIndent1"><span class="glyph">●</span>Odynophagia</p><p class="bulletIndent1"><span class="glyph">●</span>Persistent vomiting</p><p class="bulletIndent1"><span class="glyph">●</span>Gastrointestinal cancer in a first-degree relative</p><p></p><p class="headingAnchor" id="H3134811784"><span class="h4">Risk factors for Barrett's esophagus</span><span class="headingEndMark"> — </span>Screening for Barrett's esophagus is typically recommended for patients with multiple risk factors (one of which must be duration of GERD of at least 5 to 10 years). </p><p>Risk factors for Barrett's esophagus include:</p><p class="bulletIndent1"><span class="glyph">●</span>Duration of GERD of at least 5 to 10 years</p><p class="bulletIndent1"><span class="glyph">●</span>Age 50 years or older</p><p class="bulletIndent1"><span class="glyph">●</span>Male sex</p><p class="bulletIndent1"><span class="glyph">●</span>White individuals</p><p class="bulletIndent1"><span class="glyph">●</span>Hiatal hernia</p><p class="bulletIndent1"><span class="glyph">●</span>Obesity</p><p class="bulletIndent1"><span class="glyph">●</span>Nocturnal reflux</p><p class="bulletIndent1"><span class="glyph">●</span>Tobacco use (past or current)</p><p class="bulletIndent1"><span class="glyph">●</span>First-degree relative with Barrett's esophagus and/or adenocarcinoma</p><p></p><p>Multiple societies have issued guidelines regarding screening patients for Barrett's esophagus with varying recommendations. These are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/2269.html" rel="external">"Barrett's esophagus: Epidemiology, clinical manifestations, and diagnosis", section on 'Screening patients for Barrett's esophagus'</a>.)</p><p class="headingAnchor" id="H1080948294"><span class="h4">Abnormal upper gastrointestinal tract imaging</span><span class="headingEndMark"> — </span>Abdominal imaging is not required to establish the diagnosis of GERD but may have been performed for evaluation of concurrent symptoms. In such cases, luminal imaging abnormalities in the upper gastrointestinal tract may warrant diagnostic evaluation with upper endoscopy.</p><p class="headingAnchor" id="H82189930"><span class="h3">Endoscopic findings</span><span class="headingEndMark"> — </span>Upper endoscopy may be normal in patients with GERD, or there may be evidence of esophagitis of varying degrees [<a href="#rid17">17</a>]. Among untreated GERD patients, approximately 30 percent will have endoscopic esophagitis. The severity and duration of symptoms correlate poorly with the severity of esophagitis. </p><p>In contrast to infectious and medication-induced esophagitis, which tend to be in the mid-esophagus, the ulcerations seen in peptic esophagitis are usually irregularly shaped or linear, multiple, and are in the very distal esophagus. (See  <a class="medical medical_review" href="/z/d/html/2255.html" rel="external">"Pill esophagitis", section on 'Upper endoscopy and biopsy in selected patients'</a> and  <a class="medical medical_review" href="/z/d/html/2241.html" rel="external">"Approach to the evaluation of dysphagia in adults", section on 'Infectious esophagitis'</a>.)</p><p>Other endoscopic findings in patients with longstanding GERD include peptic strictures, Barrett's metaplasia, and esophageal adenocarcinoma. (See  <a class="medical medical_review" href="/z/d/html/2263.html" rel="external">"Complications of gastroesophageal reflux in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Grading the severity of esophagitis </strong>– Erosive esophagitis is graded according to its severity to guide management. Several endoscopic grading schemes have been devised to decrease inter-operator variability of endoscopy in assessing the severity of peptic esophagitis. Of these, the Los Angeles classification is the most thoroughly evaluated classification for esophagitis and is the most widely used [<a href="#rid18">18</a>]. (See  <a class="medical medical_review" href="/z/d/html/2258.html" rel="external">"Medical management of gastroesophageal reflux disease in adults", section on 'Recurrent symptoms'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Los Angeles classification – The Los Angeles classification grades esophagitis severity by the extent of mucosal abnormality, with complications recorded separately. In this grading scheme, a mucosal break refers to an area of slough adjacent to more normal mucosa in the squamous epithelium with or without overlying exudate.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Grade A – One or more mucosal breaks each ≤5 mm in length  (<a class="graphic graphic_picture graphicRef60311" href="/z/d/graphic/60311.html" rel="external">picture 1</a>)</p><p class="bulletIndent3"><span class="glyph">-</span>Grade B – At least one mucosal break &gt;5 mm long, but not continuous between the tops of adjacent mucosal folds  (<a class="graphic graphic_picture graphicRef74162" href="/z/d/graphic/74162.html" rel="external">picture 2</a>)</p><p class="bulletIndent3"><span class="glyph">-</span>Grade C – At least one mucosal break that is continuous between the tops of adjacent mucosal folds, but which is not circumferential  (<a class="graphic graphic_picture graphicRef53483" href="/z/d/graphic/53483.html" rel="external">picture 3</a>)</p><p class="bulletIndent3"><span class="glyph">-</span>Grade D – Mucosal break that involves at least three-fourths of the luminal circumference  (<a class="graphic graphic_picture graphicRef63178" href="/z/d/graphic/63178.html" rel="external">picture 4</a>)</p><p></p><p class="headingAnchor" id="H3968135477"><span class="h3">Histology</span><span class="headingEndMark"> — </span>Approximately two-thirds of patients with symptoms of GERD and no visible endoscopic findings (ie, nonerosive reflux disease) have histologic evidence of esophageal injury that responds to acid suppression [<a href="#rid19">19</a>]. However, histology is not specific for GERD and similar findings may be seen in patients with eosinophilic esophagitis. The most consistently observed histologic finding of GERD is the dilation of the intercellular spaces seen on transmission electron microscopy. Other histologic features include the presence of neutrophils and eosinophils, dilated vascular channels in papillae of the lamina propria, thickening of the basal cell layer with pale, distended squamous ("balloon") cells, and elongation of the papillae of the epithelium  (<a class="graphic graphic_picture graphicRef56086" href="/z/d/graphic/56086.html" rel="external">picture 5</a>). (See  <a class="medical medical_review" href="/z/d/html/2243.html" rel="external">"Clinical manifestations and diagnosis of eosinophilic esophagitis (EoE)", section on 'Histology'</a>.)</p><p>Cytokine triggered inflammation stimulates histopathological events in the development of esophagitis. Lymphocytic inflammation and dilated intercellular spaces occur deep in the epithelium, not at the luminal surface, and regenerative changes (basal cell hyperplasia, papillary elongation) are initiated prior to the development of surface necrosis. (See  <a class="medical medical_review" href="/z/d/html/2257.html" rel="external">"Pathophysiology of reflux esophagitis", section on 'Mechanisms of gastroesophageal reflux disease'</a>.)</p><p class="headingAnchor" id="H11"><span class="h2">Esophageal manometry</span><span class="headingEndMark"> — </span>In patients with suspected GERD with chest pain and/or dysphagia and a normal upper endoscopy, an esophageal manometry should be performed to exclude an esophageal motility disorder. Manometry is useful in ensuring that ambulatory pH probes are placed correctly but cannot diagnose GERD. It is also used to evaluate peristaltic function before antireflux surgery for GERD [<a href="#rid20">20</a>]. (See  <a class="medical medical_review" href="/z/d/html/2278.html" rel="external">"Surgical treatment of gastroesophageal reflux in adults"</a> and  <a class="medical medical_review" href="/z/d/html/2239.html" rel="external">"Approach to refractory gastroesophageal reflux disease in adults", section on 'Residual acid reflux'</a>.)</p><p class="headingAnchor" id="H4287910141"><span class="h2">Ambulatory esophageal pH monitoring</span><span class="headingEndMark"> — </span>Ambulatory pH monitoring is also used to confirm the diagnosis of GERD in those with persistent symptoms (whether typical or atypical, particularly if a trial of twice-daily PPI has failed) or to monitor the adequacy of treatment in those with continued symptoms [<a href="#rid21">21,22</a>]. The approach to management of patients with refractory GERD is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/2239.html" rel="external">"Approach to refractory gastroesophageal reflux disease in adults", section on 'Esophageal impedance pH testing'</a>.)</p><p>Ambulatory pH monitoring can be performed with either a transnasally placed catheter or a wireless, capsule-shaped device that is affixed to the distal esophageal mucosa [<a href="#rid23">23,24</a>]. Esophageal pH monitoring with impedance is an alternative to wired or wireless pH studies with the advantage of detecting weakly acid reflux in addition to acid reflux, making it more useful in ascertaining symptom-reflux correlation.</p><p>In each case, the pH sensor is coupled with compact, portable data recorders, and computerized data analysis. The catheter type pH electrode is positioned 5 cm above the manometrically defined upper limit of the lower esophageal sphincter. In the case of the wireless device, the pH capsule is attached 6 cm proximal to the endoscopically defined squamocolumnar junction. Tests are traditionally conducted for a 24-hour period with patients advised to consume an unrestricted diet. Studies with the wireless device are conducted for two to four days, potentially varying the dietary and/or therapeutic circumstances among days [<a href="#rid25">25</a>]. Increasing the monitoring period in patients undergoing evaluation using a wireless device increases the yield of the study for detecting reflux episodes and correlating those events with symptoms [<a href="#rid24">24,26</a>]. (See  <a class="medical medical_review" href="/z/d/html/2248.html" rel="external">"Esophageal multichannel intraluminal impedance testing"</a>.)</p><p class="headingAnchor" id="H2428379763"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of gastroesophageal reflux disease (GERD) includes infectious esophagitis, pill esophagitis, and eosinophilic esophagitis. Other causes of dysphagia include esophageal rings/webs, and impaired peristalsis due to an esophageal motility disorder. Slowly progressive dysphagia for solids with episodic esophageal obstruction is suggestive of a stricture or an esophageal cancer. Odynophagia may be due to infectious or medication-induced esophagitis. GERD can be distinguished from these conditions by esophageal manometry and upper endoscopy with biopsies of the esophagus. The differential diagnosis and evaluation of patients with dysphagia is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/2241.html" rel="external">"Approach to the evaluation of dysphagia in adults", section on 'Symptom-based differential diagnosis'</a>.)</p><p>Frequent heartburn may also be due to reflux hypersensitivity or functional heartburn. GERD can be distinguished from these conditions by pH or pH-impedance testing. Patients with reflux hypersensitivity have normal acid exposure but a positive symptom association with acid or weakly acid reflux. Patients with functional heartburn have normal acid exposure and a negative symptom reflux association. Patients with functional dyspepsia have heartburn in one third of cases, but early satiety and postprandial fullness are the predominant symptoms. (See  <a class="medical medical_review" href="/z/d/html/2239.html" rel="external">"Approach to refractory gastroesophageal reflux disease in adults", section on 'Functional heartburn'</a> and  <a class="medical medical_review" href="/z/d/html/19.html" rel="external">"Functional dyspepsia in adults", section on 'Clinical manifestations'</a>.) </p><p class="headingAnchor" id="H3634733802"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/116050.html" rel="external">"Society guideline links: Gastroesophageal reflux in adults"</a>.)</p><p class="headingAnchor" id="H1900302256"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/15325.html" rel="external">"Patient education: Acid reflux and GERD in adults (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/15732.html" rel="external">"Patient education: Upper endoscopy (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/138520.html" rel="external">"Patient education: Esophagitis (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/2011.html" rel="external">"Patient education: Gastroesophageal reflux disease in adults (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/1992.html" rel="external">"Patient education: Upper endoscopy (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H18"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Terminology</strong> – Physiologic reflux episodes typically occur postprandially, are short-lived, asymptomatic, and rarely occur during sleep. Gastroesophageal reflux disease (GERD) is a condition that develops when the reflux of stomach contents causes troublesome symptoms and/or complications. (See <a class="local">'Terminology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> – The estimated prevalence of GERD is approximately 10 to 20 percent of individuals in the Western world and less than 5 percent in Asia. However, prevalence estimates are limited by the assumption that heartburn and/or regurgitation are the only indicators of the disease. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – Classic symptoms of GERD are heartburn (pyrosis) and regurgitation. Other symptoms of GERD include dysphagia, chest pain, water brash, globus sensation, odynophagia, extraesophageal symptoms (eg, chronic cough, hoarseness, wheezing), and infrequently, nausea. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis of GERD can be based upon clinical symptoms alone in patients with classic symptoms. In patients without classic symptoms of GERD, other disorders need to be excluded before attributing the symptoms to GERD. (See <a class="local">'Patients with classic symptoms'</a> above and <a class="local">'Patients without classic symptoms'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Additional evaluation in selected patients</strong> – Additional evaluation is required in selected patients with suspected GERD to rule out alternative etiologies, confirm the diagnosis of GERD, and assess for complications (eg, Barrett’s esophagus).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Indications for upper endoscopy</strong> – Upper endoscopy with biopsy should be performed at presentation for patients with an esophageal GERD syndrome with any of the following:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Alarm features suggestive of a gastrointestinal malignancy</p><p class="bulletIndent3"><span class="glyph">-</span>Abnormal upper GI tract imaging</p><p class="bulletIndent3"><span class="glyph">-</span>Risk factors for Barrett's esophagus</p><p class="bulletIndent3"><span class="glyph utd-adt-cnt utd-adt-pathwys">-</span>Patients with suspected GERD who have not responded to an empirical trial of twice-daily proton pump inhibitor (PPI) therapy. (See <a class="local">'Evaluation in selected patients'</a> above.) <span class="utd-adt-cnt utd-adt-pathwys utd-content-120419">(Related Pathway(s):  <a class="utd-content-120419" href="/pathway/120419?topicRef=2265&amp;source=see_link">Gastroesophageal reflux disease: Identification of adults who require upper endoscopy</a>.)</span></p><p></p><p class="bulletIndent2">Alarm features that are suggestive of a gastrointestinal malignancy include:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>New onset of dyspepsia in patient ≥60 years</p><p class="bulletIndent3"><span class="glyph">-</span>Evidence of gastrointestinal bleeding (hematemesis, melena, hematochezia, occult blood in stool)</p><p class="bulletIndent3"><span class="glyph">-</span>Iron deficiency anemia</p><p class="bulletIndent3"><span class="glyph">-</span>Anorexia</p><p class="bulletIndent3"><span class="glyph">-</span>Unexplained weight loss</p><p class="bulletIndent3"><span class="glyph">-</span>Dysphagia</p><p class="bulletIndent3"><span class="glyph">-</span>Odynophagia</p><p class="bulletIndent3"><span class="glyph">-</span>Persistent vomiting</p><p class="bulletIndent3"><span class="glyph">-</span>Gastrointestinal cancer in a first-degree relative</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Ambulatory pH monitoring for persistent symptoms despite PPI therapy </strong>– Ambulatory pH monitoring is also used to confirm the diagnosis of GERD in those with persistent symptoms (whether typical or atypical, particularly if a trial of twice-daily PPI has failed) or to monitor the adequacy of treatment in those with continued symptoms. (See <a class="local">'Ambulatory esophageal pH monitoring'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Esophageal manometry in patients with chest pain and/or dysphagia </strong>– We perform an esophageal manometry to exclude an esophageal motility disorder in patients with chest pain and a normal upper endoscopy. Manometry is also performed to evaluate esophageal peristaltic function prior to antireflux surgery. (See <a class="local">'Esophageal manometry'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Richter JE. Typical and atypical presentations of gastroesophageal reflux disease. The role of esophageal testing in diagnosis and management. Gastroenterol Clin North Am 1996; 25:75.</a></li><li><a class="nounderline abstract_t">Vakil N, van Zanten SV, Kahrilas P, et al. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006; 101:1900.</a></li><li><a class="nounderline abstract_t">Dent J, El-Serag HB, Wallander MA, Johansson S. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut 2005; 54:710.</a></li><li><a class="nounderline abstract_t">Camilleri M, Dubois D, Coulie B, et al. Prevalence and socioeconomic impact of upper gastrointestinal disorders in the United States: results of the US Upper Gastrointestinal Study. Clin Gastroenterol Hepatol 2005; 3:543.</a></li><li><a class="nounderline abstract_t">Zagari RM, Fuccio L, Wallander MA, et al. Gastro-oesophageal reflux symptoms, oesophagitis and Barrett's oesophagus in the general population: the Loiano-Monghidoro study. Gut 2008; 57:1354.</a></li><li><a class="nounderline abstract_t">Vakil NB, Traxler B, Levine D. Dysphagia in patients with erosive esophagitis: prevalence, severity, and response to proton pump inhibitor treatment. Clin Gastroenterol Hepatol 2004; 2:665.</a></li><li><a class="nounderline abstract_t">Kahrilas PJ, Hughes N, Howden CW. Response of unexplained chest pain to proton pump inhibitor treatment in patients with and without objective evidence of gastro-oesophageal reflux disease. Gut 2011; 60:1473.</a></li><li><a class="nounderline abstract_t">Kwiatek MA, Mirza F, Kahrilas PJ, Pandolfino JE. Hyperdynamic upper esophageal sphincter pressure: a manometric observation in patients reporting globus sensation. Am J Gastroenterol 2009; 104:289.</a></li><li><a class="nounderline abstract_t">Brzana RJ, Koch KL. Gastroesophageal reflux disease presenting with intractable nausea. Ann Intern Med 1997; 126:704.</a></li><li><a class="nounderline abstract_t">Sellar RJ, De Caestecker JS, Heading RC. Barium radiology: a sensitive test for gastro-oesophageal reflux. Clin Radiol 1987; 38:303.</a></li><li><a class="nounderline abstract_t">DeVault KR, Castell DO. Guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Practice Parameters Committee of the American College of Gastroenterology. Arch Intern Med 1995; 155:2165.</a></li><li class="breakAll">Levine MS. Gastroesophageal reflux disease. In: Radiology of the Esophagus, Levine MS (Ed), WB Saunders, Philadelphia 1989. p.1147.</li><li><a class="nounderline abstract_t">Giannini EG, Zentilin P, Dulbecco P, et al. Management strategy for patients with gastroesophageal reflux disease: a comparison between empirical treatment with esomeprazole and endoscopy-oriented treatment. Am J Gastroenterol 2008; 103:267.</a></li><li><a class="nounderline abstract_t">Bytzer P, Jones R, Vakil N, et al. Limited ability of the proton-pump inhibitor test to identify patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol 2012; 10:1360.</a></li><li><a class="nounderline abstract_t">Numans ME, Lau J, de Wit NJ, Bonis PA. Short-term treatment with proton-pump inhibitors as a test for gastroesophageal reflux disease: a meta-analysis of diagnostic test characteristics. Ann Intern Med 2004; 140:518.</a></li><li><a class="nounderline abstract_t">Gonsalves N, Policarpio-Nicolas M, Zhang Q, et al. Histopathologic variability and endoscopic correlates in adults with eosinophilic esophagitis. Gastrointest Endosc 2006; 64:313.</a></li><li><a class="nounderline abstract_t">Adanir H, Baş B, Pakoz B, et al. Endoscopic Findings of Gastro-Esophageal Reflux Disease in Elderly and Younger Age Groups. Front Med (Lausanne) 2021; 8:606205.</a></li><li><a class="nounderline abstract_t">Lundell LR, Dent J, Bennett JR, et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut 1999; 45:172.</a></li><li><a class="nounderline abstract_t">Dent J. Microscopic esophageal mucosal injury in nonerosive reflux disease. Clin Gastroenterol Hepatol 2007; 5:4.</a></li><li><a class="nounderline abstract_t">Kahrilas PJ, Shaheen NJ, Vaezi MF, et al. American Gastroenterological Association Medical Position Statement on the management of gastroesophageal reflux disease. Gastroenterology 2008; 135:1383.</a></li><li><a class="nounderline abstract_t">Hirano I, Richter JE, Practice Parameters Committee of the American College of Gastroenterology. ACG practice guidelines: esophageal reflux testing. Am J Gastroenterol 2007; 102:668.</a></li><li><a class="nounderline abstract_t">Kahrilas PJ, Quigley EM. Clinical esophageal pH recording: a technical review for practice guideline development. Gastroenterology 1996; 110:1982.</a></li><li><a class="nounderline abstract_t">Pandolfino JE, Schreiner MA, Lee TJ, et al. Comparison of the Bravo wireless and Digitrapper catheter-based pH monitoring systems for measuring esophageal acid exposure. Am J Gastroenterol 2005; 100:1466.</a></li><li><a class="nounderline abstract_t">Yadlapati R, Masihi M, Gyawali CP, et al. Ambulatory Reflux Monitoring Guides Proton Pump Inhibitor Discontinuation in Patients With Gastroesophageal Reflux Symptoms: A Clinical Trial. Gastroenterology 2021; 160:174.</a></li><li><a class="nounderline abstract_t">Garrean CP, Zhang Q, Gonsalves N, Hirano I. Acid reflux detection and symptom-reflux association using 4-day wireless pH recording combining 48-hour periods off and on PPI therapy. Am J Gastroenterol 2008; 103:1631.</a></li><li><a class="nounderline abstract_t">Chander B, Hanley-Williams N, Deng Y, Sheth A. 24 Versus 48-hour bravo pH monitoring. J Clin Gastroenterol 2012; 46:197.</a></li></ol></div><div id="topicVersionRevision">Topic 2265 Version 35.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8682579" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Typical and atypical presentations of gastroesophageal reflux disease. The role of esophageal testing in diagnosis and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16928254" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15831922" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Epidemiology of gastro-oesophageal reflux disease: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15952096" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Prevalence and socioeconomic impact of upper gastrointestinal disorders in the United States: results of the US Upper Gastrointestinal Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18424568" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Gastro-oesophageal reflux symptoms, oesophagitis and Barrett's oesophagus in the general population: the Loiano-Monghidoro study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15290658" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Dysphagia in patients with erosive esophagitis: prevalence, severity, and response to proton pump inhibitor treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21508423" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Response of unexplained chest pain to proton pump inhibitor treatment in patients with and without objective evidence of gastro-oesophageal reflux disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19174789" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Hyperdynamic upper esophageal sphincter pressure: a manometric observation in patients reporting globus sensation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9139556" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Gastroesophageal reflux disease presenting with intractable nausea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3581674" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Barium radiology: a sensitive test for gastro-oesophageal reflux.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7487238" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Practice Parameters Committee of the American College of Gastroenterology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7487238" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Practice Parameters Committee of the American College of Gastroenterology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18289194" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Management strategy for patients with gastroesophageal reflux disease: a comparison between empirical treatment with esomeprazole and endoscopy-oriented treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22813439" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Limited ability of the proton-pump inhibitor test to identify patients with gastroesophageal reflux disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15068979" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Short-term treatment with proton-pump inhibitors as a test for gastroesophageal reflux disease: a meta-analysis of diagnostic test characteristics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16923475" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Histopathologic variability and endoscopic correlates in adults with eosinophilic esophagitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34957130" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Endoscopic Findings of Gastro-Esophageal Reflux Disease in Elderly and Younger Age Groups.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10403727" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17157563" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Microscopic esophageal mucosal injury in nonerosive reflux disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18789939" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : American Gastroenterological Association Medical Position Statement on the management of gastroesophageal reflux disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17335450" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : ACG practice guidelines: esophageal reflux testing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8964428" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Clinical esophageal pH recording: a technical review for practice guideline development.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15984967" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Comparison of the Bravo wireless and Digitrapper catheter-based pH monitoring systems for measuring esophageal acid exposure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32949568" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Ambulatory Reflux Monitoring Guides Proton Pump Inhibitor Discontinuation in Patients With Gastroesophageal Reflux Symptoms: A Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18557714" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Acid reflux detection and symptom-reflux association using 4-day wireless pH recording combining 48-hour periods off and on PPI therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21959323" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : 24 Versus 48-hour bravo pH monitoring.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
